In the PIONEER-6 study, proliferative retinopathy and macular edema requiring treatment were exclusion criteria
Goldney J, Davies MJ
The company says the new program will complement weight-loss prescriptions issued through Sequence integration or the patient's primary-care doctor
Specifications and Documentation
When fat becomes dysfunctional, it can contribute to chronic conditions like: Type 2 diabetes Fatty liver disease PCOS and hormonal imbalance Chronic fatigue and inflammation Cardiovascular risk So, this isnt just about eating less or moving more. Its about understanding the biology behind behavior, and treating the person, not just the symptom
Gastrointestinal AE with cagrisema were more than with semagutide or cagrilintide monotherapy, however the SAE and AE leading to medication discontinuation were minimal and similar between the groups [87, 90] A programme of phase 3 clinical trials (REDEFINE) assessing the safety and efficacy of cagrisema in people with obesity (NCT05567796, NCT05394519, NCT05813925) is currently ongoing